[1] SHEPARD CW，SIMARD EP，FINELLI L，et al. Hepatitis B virus infection：epidemiology and vaccination[J]. Epidemiol Rev，2006，28：112-125. [2] SELLS MA，CHEN ML，ACS G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA[J]. Proc Natl Acad Sci USA，1987，84（4）：1005-1009. [3] SELLS MA，ZELENT AZ，SHVARDSMAN M，et al. Replicative intermediates of Hepatitis B Virus in HepG2 cells that produce infectious virions[J]. J Virol， 1988，62（8）：2836-2844. [4] 张秋，孙汶生，高丽芬，等. 3.0倍乙型肝炎病毒全基因真核表达载体的构建及表达[J]. 中国现代普通外科进展，2004，7（5）：278-280. [5] 倪宏，骆抗先，朱幼芙，等. 乙型肝炎病毒全基因在肝癌细胞中的转染与表达[J]. 第一军医大学学报，2001，21（7）：501-502. [6] HE TC，ZHOU S，COSTA LT，et al. A simplified system for generating recombinant adenoviruses[J]. Proc Natl Acad Sci USA，1998，95（5）：2509-2514. [7] WEISS L，KEKULE AS，JAKUBOWSKI U，et al. The HBV-producing cell line HepG2-4A5：A new in vitro system for studying the regulation of HBV replication and for screening anti-hepatitis B virus drugs[J]. Virology，1996，216：214-218. [8] YANG HL，WESTLAND C，XIONG S，et al. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector[J]. Antiviral Res，2004，61：27-36. [9] FU L，CHENG YC. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine-and penciclovir-resistant virus[J]. Antimicrob Agents Chemother，2000，44（12）：3402-3407. [10] SUN DX，NASSAL M. Stable HepG2-and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus[J]. J Hepatol，2006，45：636-645. [11] DELANEY WE，EDWARDS R，COLLEDGE D，et al. Cross-Resistance Testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus[J]. Antimicrob Agents Chemother，2001，45（6）：1705-1713. [12] QI X，XIONG S，YANG H，et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents[J]. Antivir Ther，2007，12（3）：355-362. [13] WALTERS KA，TIPPLES GA，ALLEN MI，et al. Generation of stable cell lines expressing lamivudine-resistant hepatitis B virus for antiviral-compound screening[J]. Antimicrob Agents Chemother，2003，47（6）：1936-1942. [14] SEIFER M，PATTY A，SERRA I，et al. Telbivudine，a nucleoside analog inhibitor of HBV polymerase，has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir[J]. Antiviral Res，2009，81（2）：147-155. [15] CHEN RY，EDWARDS R，SHAW T，et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro[J]. Hepatology，2003，37（1）：27-35. [16] ONO SK，KATO N，SHIRATORI Y，et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations，increasing hepatitis B virus replication and drug resistance[J]. J Clin Invest，2001，107（4）：449-455. [17] LADA O，BENHAMOU Y，CAHOUR A，et al. In vitro susceptibility of lamivudine- resistant hepatitis B virus to adefovir and tenofovir[J]. Antivir Ther，2004，9（3）：353-363. [18] LU YP，GUO T，WANG BJ，et al. Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients[J]. World J Gastroenterol，2008，14（22）：3490-3496. [19] XU WZ，FANG Y，LI D，et al. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains ofHepatitis B virus genotype C[J]. World J Gastroenterol，2008，14（23）：3733-3738.
